Transgene - Edison Group

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Oil & Gas

Real Estate

TMT

MagForce

MCap

—

Last close

-0.02

▲ 0.01 (100.00%)

DFR Gold

MCap

CAD15m

Last close

CAD0.10

▲ 0.03 (42.86%)

SenSen Networks

MCap

AUD31m

Last close

AUD0.05

▲ 0.01 (25.00%)
Sectors
Sectors
Investment Strategy
Investment Strategy
View All

Latest
Thematics
Thematics
View All Thematics

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

James Brotherton Financial Director — Tyman
Equity Research
Investor Relations
Contact us

Transgene (EU: TNG)

Currency in -

Last close As at 26/05/2023

-2.49

— 0.00 (0.00%)

Market capitalisation

209m

Overview
Financials
Research
Thematics

Edison Investment Research is terminating coverage on Transgene. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare

04.10.19

Transgene — TG4001 first efficacy data presented at ESMO

Healthcare

23.09.19

Transgene — PHOCUS turns to earlier-stage assets

Healthcare

27.03.19

Transgene — Defining data from lead assets by year-end

Healthcare

30.11.18

Transgene — TG4010 and Pexa-Vec readouts to define 2019

Sector

Healthcare

Financials

Edison Investment Research is terminating coverage on Transgene. Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Research

Healthcare

04.10.19

Transgene — TG4001 first efficacy data presented at ESMO

Healthcare

23.09.19

Transgene — PHOCUS turns to earlier-stage assets

Healthcare

27.03.19

Transgene — Defining data from lead assets by year-end

Healthcare

30.11.18

Transgene — TG4010 and Pexa-Vec readouts to define 2019

Healthcare

16.07.18

Transgene — Near-term data to define long-term strategy

Healthcare

23.03.18

Transgene — 2018: A year of clinical data

Healthcare

01.11.17

Transgene — Multiple assets in the clinic as data readouts near

Healthcare

24.03.17

Transgene — Combination trials start, FY16 results

View All

Thematics

Healthcare

26.01.23

Machine learning in drug development

Healthcare

06.01.23

Outlook for 2023: Biotechs remain central to novel drug development

Cancer cells

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

cell DNA double helix

Healthcare

20.12.22

Cell and gene therapies

View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free